Cargando…

Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review

Visceral leishmaniasis, also known as kala-azar is one of the most commonly neglected tropical diseases affecting a large number of rural and resource-limited people in South Asia, Africa, and South America. Paromomycin, an aminoglycoside drug, is frequently used for the treatment of visceral leishm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pokharel, Pashupati, Ghimire, Rakesh, Lamichhane, Pratik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328727/ https://www.ncbi.nlm.nih.gov/pubmed/34349806 http://dx.doi.org/10.1155/2021/8629039

Ejemplares similares

Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
por: Wiwanitkit, Viroj
Publicado: (2012)

Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis
por: Sundar, Shyam, et al.
Publicado: (2014)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
por: Rahman, Ridwanur, et al.
Publicado: (2017)

Phase 4 Pharmacovigilance Trial of Paromomycin Injection for the Treatment of Visceral Leishmaniasis in India
por: Sinha, Prabhat K., et al.
Publicado: (2011)

Effectiveness of Paromomycin on Cutaneous Leishmaniasis in Iran: A Systematic Review and Meta-Analysis
por: Moradzadeh, Rahmatollah, et al.
Publicado: (2019)

Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
por: Jamil, Kazi M., et al.
Publicado: (2015)

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
por: Musa, Ahmed M., et al.
Publicado: (2010)

Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2017)

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
por: Verrest, Luka, et al.
Publicado: (2023)

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients
por: Verrest, Luka, et al.
Publicado: (2021)

Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
por: Kimutai, Robert, et al.
Publicado: (2017)

Topical paromomycin for New World cutaneous leishmaniasis
por: Sosa, Néstor, et al.
Publicado: (2019)

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial
por: Hailu, Asrat, et al.
Publicado: (2010)

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
por: Musa, Ahmed, et al.
Publicado: (2012)

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
por: Musa, Ahmed M, et al.
Publicado: (2022)

Topical Paromomycin and Gentamicin for New World Cutaneous Leishmaniasis in Panama
por: Monge-Maillo, Begoña, et al.
Publicado: (2014)

Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis
por: Parvez, Shabi, et al.
Publicado: (2020)

Nanoemulsions with Chloroaluminium Phthalocyanine and Paromomycin for Combined Photodynamic and Antibiotic Therapy for Cutaneous Leishmaniasis
por: Leal Pinto, Sandra Milena, et al.
Publicado: (2021)

Factors affecting length of hospital stay in chronic obstructive pulmonary disease patients in a tertiary hospital of Nepal: A retrospective cross-sectional study
por: Pokharel, Pashupati, et al.
Publicado: (2022)

Epidemiology of visceral leishmaniasis
por: Ready, Paul D
Publicado: (2014)

Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia
por: Mengstie, Tiget Ayelgn, et al.
Publicado: (2021)

Is Paromomycin an Effective and Safe Treatment against Cutaneous Leishmaniasis? A Meta-Analysis of 14 Randomized Controlled Trials
por: Kim, Dae Hyun, et al.
Publicado: (2009)

Randomized, Double-Blinded, Phase 2 Trial of WR 279,396 (Paromomycin and Gentamicin) for Cutaneous Leishmaniasis in Panama
por: Sosa, Néstor, et al.
Publicado: (2013)

Paromomycin Affects Translation and Vesicle-Mediated Trafficking as Revealed by Proteomics of Paromomycin –Susceptible –Resistant Leishmania donovani
por: Chawla, Bhavna, et al.
Publicado: (2011)

Non-adherence to anti-hypertensive medications in a low-resource country Nepal: a systematic review and meta-analysis
por: Pokharel, Pashupati, et al.
Publicado: (2023)

Drug Resistance in Visceral Leishmaniasis
por: Maltezou, Helena C.
Publicado: (2010)

Therapeutic Options for Visceral Leishmaniasis
por: Monge-Maillo, Begoña, et al.
Publicado: (2013)

Visceral leishmaniasis
por: Sundar, Shyam
Publicado: (2015)

Visceral Leishmaniasis in Southeastern Iran: A Narrative Review
por: SHARIFI, Iraj, et al.
Publicado: (2017)

Control of Visceral Leishmaniasis in Latin America—A Systematic Review
por: Romero, Gustavo A. S., et al.
Publicado: (2010)

Efficacy and community-effectiveness of insecticide treated nets for the control of visceral leishmaniasis: A systematic review
por: Montenegro-Quiñonez, Carlos Alberto, et al.
Publicado: (2022)

Is the cat an important reservoir host for visceral leishmaniasis? A systematic review with meta-analysis
por: Asfaram, Shabnam, et al.
Publicado: (2019)

Prevalence of visceral leishmaniasis among people with HIV: a systematic review and meta-analysis
por: Kantzanou, Maria, et al.
Publicado: (2022)

Utility of chest imaging in the diagnosis and management of patients with visceral leishmaniasis: A systematic review
por: Hailemariam, Tesfahunegn, et al.
Publicado: (2023)

Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia
por: Tamiru, Aschalew, et al.
Publicado: (2021)

Visceral leishmaniasis in Iran: Review of the Epidemiological and Clinical Features
por: Mohebali, Mehdi
Publicado: (2013)

Visceral Leishmaniasis in Ethiopia: An Evolving Disease
por: Leta, Samson, et al.
Publicado: (2014)

Determinants for the Development of Visceral Leishmaniasis Disease
por: McCall, Laura-Isobel, et al.
Publicado: (2013)

Eco-epidemiology of visceral leishmaniasis in Ethiopia
por: Gadisa, Endalamaw, et al.
Publicado: (2015)

Visceral leishmaniasis in Somalia: A review of epidemiology and access to care
por: Sunyoto, Temmy, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lge2dtosvv6t432mfum87d9940